← All earnings call summaries
Clean Science and Technology Limited — Q1FY27 Earnings Call Summary
Key Takeaways
- Supply chain disruptions impacted volumes in Q1; improvements expected in Q2 but raw material price volatility remains
- EBITDA margins expected to improve with higher grade HALS sales and operational efficiencies
- Q1 FY27 consolidated revenue grew 10% y-y to INR 264 Cr; standalone revenue down 6% y-y but up 5% q-o-q to INR 203 Cr
- Strategic collaboration with Swiss partner Geneus Chem for advanced HALS technology; expected INR 300-350 Cr incremental revenue over 3-4 years
- Hydroquinone and catechol plant stabilized; commercial supplies ramping from Q2 FY27
- Performance Chemical 2 plant expected commercial start in Q3 FY27 (Nov-Dec 2026)
- Long-term contract with Kemin for key ingredients with 5-year supply commitment; capacity expansion underway
- EBITDA margin at 37% consolidated, 43% standalone; PAT margin 28% consolidated, 36% standalone
- Export approvals and commercial shipments for HALS ramping up, supporting growth and margin expansion
- HALS sales now 22% of consolidated revenue, with exports contributing nearly 50% of HALS sales
📄 Source: View original transcript (PDF)
Get Clean Science and Technology Limited earnings summaries on Telegram
Add Clean Science and Technology Limited to your watchlist. Receive AI-generated summaries within hours of every earnings call.
Start free →
Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.